Royalty Report: Drugs, Therapeutic, Delivery – Collection: 27993

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Therapeutic
  • Delivery
  • Pharmaceuticals
  • Disease
  • Vaccine
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27993

License Grant
The Company hereby grants the exclusive right and license in, to, and under the Novavax IP in the Field within the Territory.  The exclusive license shall be for the period in which any Novavax IP or patents covering the Joint Improvement(s) shall remain valid and enforceable, unless earlier terminated as provided.
License Property
The Licensor has certain proprietary know-how in the field of encapsulated drug delivery systems and has developed certain proprietary adjuvants, such as a Novasome® delivery system; and the Licensee has certain proprietary know-how in the field of vaccines and has developed and continues to develop proprietary vaccines, especially a vaccine comprising antigenic determinants of an influenza virus.

The parties desire for Licensee to develop, manufacture, market, distribute and sell a product for treating or preventing influenza virus and/or infection, such as a vaccine comprising antigenic determinants of an influenza virus, like Fluogen®, which includes a proprietary adjuvant developed by Licensor.

Field of Use
Field shall mean (a) the use of Novavax IP in any manner whatsoever to develop, create, invent, manufacture, promote, market, offer-for-sale, sell, import and/or export an Influenza Product involved in or concerned with the treatment or prevention of influenza virus or any other purpose for which an Influenza Product may be indicated, and (b) the subsequent exploitation of an Influenza Product in the territory.

IPSCIO Record ID: 4244

License Grant
The Licensor entered into a License Agreement with the Korean Licensee, to develop, manufacture and commercialize influenza vaccines using the Licensee's proprietary VLP technology.
License Property
The Licensor is a clinical-stage biopharmaceutical company focused on developing novel and effective recombinant vaccines. These vaccines leverage the Licensor's platform technology coupled with a single-use bioprocessing production system to develop virus-like particle (VLP) vaccines, as well as recombinant nanoparticle vaccines.

VLPs are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Company’s VLPs resemble the virus they were engineered to mimic, but lack the genetic material to replicate the virus and its single-use bioprocessing production technology uses insect cells rather than chicken eggs or mammalian cells.

The Licensor’s current product targets include VLP vaccines against seasonal and pandemic (including H5N1) influenza and a recombinant nanoparticle vaccine against Respiratory Syncytial Virus (RSV).

The upfront payment has been deferred and will be recognized as revenue when certain obligations in the agreement are satisfied.

Field of Use
At its own cost, the Licensee is responsible for funding its clinical development of the influenza VLP vaccines and completing a manufacturing facility in South Korea.

IPSCIO Record ID: 7238

License Grant
The Australian Licensor Licensed zanamivir on an exclusive, worldwide basis to the Belgium Licensee, which markets the product as Relenzaâ„¢.
License Property
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses.

Neuraminidase inhibitors work against influenza by preventing viruses from being released from infected cells and subsequently infecting further cells. Neuraminidase inhibitors are usually prescribed to patients presenting with flu-like symptoms during epidemic periods to reduce symptoms or prevent spread of the virus.

Field of Use
The Licensor's zanamivir, was developed as the first-in-class NI to treat influenza.

IPSCIO Record ID: 299287

License Grant
Licensor grants to the Licensee of Korea an exclusive right and license in the Field under the Licensor Patent Rights, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale  Licensor Licensed Products in the Territory only.
License Property
Licensor has a universal influenza vaccine delivered with electroporation, SynCon â„¢ Universal influenza DNA vaccine in conjunction with electroporation.

The patents include Improved vaccines and methods for using the same;  Novel vaccines against multiple subtypes of influenza virus;  Influenza Nucleic acid molecules and vaccines made therefrom; and, Nucleic acid molecule encoding concensus influenza a hemagglutinin H!

SynCon™ technology enables the design of “universal” DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens such as influenza.

Field of Use
Field means a limitation on the application or utilization of Patent Rights to the field of DNA based vaccines against influenza that are delivered to a subject using electroporation, and its use to treat or protect a subject by delivering to such subject along with electroporation.

IPSCIO Record ID: 179238

License Grant
Licensor and Licensee entered into a 10 year exclusive License Agreement entitling it to use the Novavax Technologies in the fields.
License Property
Novavax Technologies proprietary organized lipid structures, lipid vesicle encapsulation technologies, cellulose structures and micellar nanoparticles, that have a wide variety of applications in human vaccines and pharmaceuticals.

Liposome encapsulation is a process designed to entrap and deliver various useful materials. Prior to the development of the Novavax Technologies, the most commonly used technology, phospholipid liposome encapsulation, had a limited capacity to encapsulate anything other than materials that can be dissolved or suspended in water. Phospholipid liposomes are man-made, microscopic spheres that are usually formed through a multi-step process, which generally includes the mixing of water, organic solvents and phospholpids. Most phospholipid-based liposomes are produced from materials that are expensive and may require the use of potentially hazardous organic solvents. The standard, multi-step phospholipid manufacturing process yields small quantities of expensive, less stable vesicles with limited cargo capacity.

Field of Use
This agreement pertains to the drug industry relating to therapeutic products for human infectious diseases, including new vaccines, new adjuvants for vaccines, anti-bacterial and anti-viral products and formulations for topical drug delivery in the fields of (i) animal pharmaceuticals, biologicals and other animal health products; (ii) foods, food applications, nutrients and flavorings; (iii) cosmetics, consumer products and dermatological over-the-counter and prescription products (excluding certain topically delivered hormones); (iv) fragrances; and (v) chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals and other specialty chemicals.

IPSCIO Record ID: 394

License Grant
The Licensor and Licensee entered into an exclusive, worldwide license agreement whereby we granted the Licensee the right to use our TranzFect technology in DNA-based vaccines targeted to four infectious diseases, one of which is HIV.
License Property
TranzFect is a delivery technology for DNA-based vaccines.

U.S. Patent
5,554,372 (subject to U.S. government regulations)
5,990,241
6,086,899

RE 36,665
5,567,859
5,696,298
5,824,322

Pending application 90/104,088

Foreign
W096/04932

6,086,899

Field of Use
The HIV Field shall mean the prevention and/or treatment of infection by Human immunodeficiency Virus.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.